Enteral Feeding Devices Market Size, Share & Trends Analysis Report By Product (Giving Set, Enteral Feeding Pump, Percutaneous Endoscopic Gastrostomy Device), By Age Group, By Indication, By End Use, By Region, And Segment Forecasts, 2023 - 2032

The global enteral feeding devices market size was valued at USD 4.1 billion in 2022 and is projected to grow at a CAGR of 4.8% from 2023 to 2032.

Key Pointers

• The enteral feeding pump segment dominated the enteral feeding devices market in 2022 with a 44.8% share as these pumps are designed for safer & more intuitive nutritional care.
• The low-profile gastrostomy device is anticipated to expand at a significant pace with a CAGR of 6.2%. 
• The adult age group segment dominated the market with a revenue share of 91.2% in 2022.
• Indication segment dominated the market with a revenue share of 34.1% in 2022. 
• Based on end use, hospitals segment dominated the market growth with 58.8% of market share in 2022.
• North America had the largest market share of 37.4% as of 2022.

Report Scope of The Enteral Feeding Devices Market:

The growing geriatric population has resulted in an increased incidence of diabetes, severe pancreatitis, and other gastrointestinal diseases, which aids market growth. In addition, the growing prevalence of these diseases in adult and pediatric populations is expected to drive the market. Adoption of the “Feed Early Enteral Diet Adequately for Maximum Effect” (FEED ME) protocol in surgical trauma ICUs in the U.S. enables subsidies on these devices. Technological advancements such as the introduction of tri-funnel replacement G-tubes and J-tubes with reverse balloon designs are also expected to aid in growth during the forecast period.

According to several NCBI studies, individuals aged over 65 years are at a greater risk of developing chronic illnesses such as Parkinson’s and nervous system disorders. According to WHO, the global population aged 60 years and above increased significantly from around 1 billion in 2020 to about 1.4 billion in 2030 and is expected to almost double by 2050 to reach around 2.1 billion. The number of elderly patients with critical illnesses has increased significantly over the past few years. The risk of malnutrition and frailty among the geriatric opulartion with comorbidities, such as stroke, depression, and dementia, is much higher, mainly owing to various age-related changes in body composition and muscle mass. This results in a reduced ability to perform Activities of Daily Living (ADLs), thereby increasing the risk of falls or injuries.

There has been a constant increase in the prevalence of chronic diseases, such as Alzheimer’s disease, Attention Deficit Hyperactivity Disorder (ADHD), osteoporosis, osteoarthritis, central nervous system disorders, and other diseases, which require clinical dietary management. Amino acid-based enteral nutrition is used in the management of sleep disorders, depression, osteoporosis, fibromyalgia, and post-traumatic stress disorder. EN is intended for the dietary management of patients with impaired or limited capacity to digest, ingest, absorb, and metabolize normal diet and patients having special nutrient requirements. Alzheimer’s disease is one of the common neurodegenerative medical conditions that lead to dementia, behavioral changes, decline in functional ability, and economic burden.

The general lack of awareness and understanding regarding enteral nutrition in the medical community is projected to limit its adoption. It requires prescription and supervision by medical professionals. Although these products are gaining acceptance, they remain poorly understood by patients, physicians, and pharmacists. Dieticians are generally aware of these products; however, most doctors and specialists lack awareness regarding the same. This factor prevents doctors from adopting or prescribing enteral nutrition, which may restrain the growth of the market. Furthermore, not all medical experts are convinced that enteral formula would be successful in the treatment of chronic conditions and their symptoms, which may negatively impact the adoption of enteral feeding products along with treatment.

Studies reported that early nutritional plan initiation among critically ill COVID-19 patients was beneficial in reducing septic complications, decreasing mortality, and shortening the hospital stays. Hence, many organizations reported the initiation of enteral nutrition among such patients. For instance, the American Society for Parenteral and Enteral Nutrition (ASPEN) issued guidelines during the pandemic to initiate enteral nutrition within 24 hours to 48 hours in patients who were unable to take or consume food voluntarily. This increased the demand for enteral feeding devices during the pandemic.

Enteral Feeding Devices Market Report Segmentation:

Product

• Giving Set
• Enteral Feeding Pump
• Percutaneous Endoscopic Gastrostomy Device
• Low Profile Gastrostomy Device
• Nasogastric Tube
• Gastrostomy Tube

Age Group

• Adults 
• Pediatrics

Indication

• Alzheimer’s
• Nutrition Deficiency
• Cancer Care
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Malabsorption/GI Disorder/Diarrhea
• Others

End Use

• Hospitals

• • Cardiology
  • Neurology
  • Critical Care (ICU)
  • Oncology
  • Others

• Home Care